



10/502,233

***** Welcome to STN International *****
***** STN Columbus *****

FILE 'HOME' ENTERED AT 10:44:51 ON 27 FEB 2007

=> file reg

=> Uploading C:\Program Files\Stnexp\Queries\10502234.str



chain nodes :

13 15 17 26 27 28

ring nodes :

1 2 3 4 5 6 7 8 9 10 18 19 20 21 22 23

chain bonds :

7-13 13-15 15-17 17-19 22-26 26-27 27-28

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 18-19 18-23 19-20 20-21
21-22 22-23

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 7-13 8-9 9-10 13-15 15-17 17-19
18-19 18-23 19-20 20-21 21-22 22-23 22-26 26-27 27-28

isolated ring systems :

containing 1 : 18 :

G1:N,C

G2:C,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:Atom 15:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom
26:CLASS 27:CLASS 28:Atom

Generic attributes :

28:


Type of Ring System : Polycyclic

L1 STRUCTURE UPLOADED

=> dis l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam

L2 6 SEA SSS SAM L1

=> s l1 full

L3 615 SEA SSS FUL L1

=> file caplus

=> s l3

L4 6 L3

=> dis l4 1-6 bib abs fhitstr

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:565041 CAPLUS Full-text

DN 141:140414

TI Preparation of quinolines and 1,5-naphthyridines as antibacterial agents

IN Axten, Jeffrey Michael; Brooks, Gerald; Brown, Pamela; Davies, David; Gallagher, Timothy Francis; Markwell, Roger Edward; Miller, William Henry; Pearson, Neil David; Seefeld, Mark

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 232 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058144	A2	20040715	WO 2003-US40032	20031217
	WO 2004058144	A3	20041021		
	W:				
	AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, EG, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003300965	A1	20040722	AU 2003-300965	20031217
	EP 1578743	A2	20050928	EP 2003-814042	20031217

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006511622 T 20060406 JP 2005-509974 20031217
 US 2006041123 A1 20060223 US 2005-538931 20050614
 PRAI US 2002-434729P P 20021218
 US 2003-457013P P 20030324
 WO 2003-US40032 W 20031217
 OS MARPAT 141:140414
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [wherein Z1 = N, CR1a and derivs.; R, R1a = independently H, halo, alkylthio, alkyl, etc.; R1CCR1a = ethylenedioxy; R1b = H, halo; with the proviso that when Z1 = N, then R1b = H, and when Z1 = CR1a, then R1 is not H; R1c = halo; AB = CHR6-CO, CHR6-CH2; R6 = H, NH2, CH2OH, OH; R3 = up to 2 substituents selected from H, halo, alkyl, hydroxyalkyl, CONH2, CO2H, CH2CONH2, etc.; R4 = UR5; R5 = (un)substituted bicycyl carbocyclyl or heterocyclyl containing up to 4 heteroatoms in each ring; U = CO, SO2, CH2; and their pharmaceutically acceptable salts] were prepared for treating bacterial infections in mammals, in particular humans. For example, II was prepared by hydrogenation of 5-benzyloxy-2-hydroxymethyl-1H-pyridin-4-one with Pd/C, cyclization with 1,2-dibromoethane, oxidation of the alc., and reductive alkylation of the amine III (preparation given) with the resulting aldehyde. Selected I displayed MIC's ≤ 2 $\mu\text{g/mL}$ against *Staphylococcus aureus*, *E. coli*, etc.

IT 724790-99-2P, (+)-6-[[[1-[2-[3-Fluoro-6-(methoxy)quinolin-4-yl]-2-hydroxyethyl]-4-piperidiny]amino]methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (antibacterial agent; preparation of quinolines and 1,5-naphthyridines as antibacterial agents)

RN 724790-99-2 CAPLUS



CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-[[[1-[2-(3-fluoro-6-methoxy-4-quinolinyl)-2-hydroxyethyl]-4-piperidiny]amino]methyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:20502 CAPLUS Full-text
 DN 140:94052
 TI Preparation of [(pyrido[3.2-b][1,4]thiazinyl)methyl]amino]piperidines and
 analogs as antibacterial agents
 IN Axten, Jeffrey Michael; Daines, Robert A.; Davies, David Thomas;
 Gallagher, Timothy Francis; Jones, Graham Elgin; Miller, William Henry;
 Pearson, Neil David; Pendrak, Israil
 PA Glaxo Group Ltd., UK
 SO PCT Int. Appl., 74 pp..
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004002490	A2	20040108	WO 2003-EP6754	20030625
	WO 2004002490	A3	20051027		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
	PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR,				
	TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003238054	A1	20040119	AU 2003-238054	20030625
	EP 1583537	A2	20051012	EP 2003-735685	20030625
	EP 1583537	A3	20051214		
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006505505	T	20060216	JP 2004-516690	20030625
	US 2006058287	A1	20060316	US 2005-518655	20050714
PRAI	US 2002-391710P	P	20020626		
	WO 2003-EP6754	W	20030625		
OS	MARPAT 140:94052				
GI					



AB Title compds. I [wherein RA = (un)substituted bicyclic carbocycle, heterocycle; R2 = H, or (un)substituted alkyl, alkenyl; R3 = H, carboxy, alkoxy, aminocarbonyl, etc.; R4 = UR5: U = CO, SO2, CH2; R5 = (un)substituted bicyclic carbocycle or heterocycle; n = 0-1; AB = aminocarbonyl, alkylcarbonyl, aminosulfonyl, etc.; and pharmaceutically

acceptable derivs. thereof] were prepared as antibacterial agents. For example, reductive alkylation of 4-[2-[(3R,4S)-4-amino-3-hydroxy-1-piperidinyl]ethyl]-6-quinolinecarbonitrile•2HCl with 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxaldehyde afforded II in 60% yield. II•2HCl had MIC ≤ 2 $\mu\text{g/mL}$ against bacterial infections, such as *S. epidermidis* CL7. Thus, I and their pharmaceutical compns. are useful for the treatment of bacterial infections in mammals, particularly in humans.


IT 642478-39-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(Preparation of [[(pyrido[3.2-b][1,4]thiazinyl)methyl]amino]piperidines and analogs as antibacterial agents)

RN 642478-39-5 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-thiazin-3(4H)-one, 6-[[[1-[2-(4-quinolinyl)ethyl]-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:610459 CAPLUS Full-text

DN 139:164795

TI Preparation of aminopiperidine compounds as antibacterial agents

IN Miller, William Henry; Pearson, Neil David; Pendrak, Israil; Seefeld, Mark Andrew

PA Glaxo Group Limited, UK; Daines, Robert A

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003064431	A2	20030807	WO 2003-EP824	20030127
	WO 2003064431	A3	20031218		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP	1470131	A2	20041027	EP 2003-734702	20030127
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
JP 2005519922	T	20050707 JP 2003-564054 20030127
US 2005085494	A1	20050421 US 2004-502234 20040722
US 7109213	B2	20060919
PRAI GB 2002-2025	A	20020129
GB 2002-29819	A	20021220
WO 2003-EP824	W	20030127
OS MARPAT 139:164795		
GI		

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; one of Z1-Z5 = N, one = CR1a and the remainder = CH; or one or two of Z1-Z5 = CR1a and the remainder are CH; R1, R1a = H, OH, alkoxy, etc.; or when Z5 = CR1a, then R1a may instead be CN, CH2OH, CO2H; or R1 and R1a on adjacent positions may together form ethylenedioxy; provided that when Z1-Z5 = CR1a or CH, then R1 is not H; R2 = H, alkyl, alkenyl, etc.; R3 is in the 2-, 3- or 4- position and is CF3 or is in the 2-position and is oxo; or R3 is in the 3-position and = F, (un)substituted NH2; R4 = UR5 (wherein U = CO, SO2, CH2; R5 = (un)substituted bicyclic carbocyclic or heterocyclic ring system); n = 0-1; A = O, (un)substituted NH, CH2; B = O, SO2, (un)substituted NH, CH2], useful in the treatment of bacterial infections in mammals (biol. data given), particularly in man, were prepared E.g., a multi-step synthesis of II and III as a 1:1 mixture of isomers (starting from Me 6-chloro-5-nitronicotinate), was given. A pharmaceutical composition comprising the title compound I was claimed.

IT 577771-02-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminopiperidine compds. as antibacterial agents)

RN 577771-02-9 CAPLUS

CN 4-Quinolinemethanol, α -[[[(3R,4S)-3-fluoro-4-[[[1,2,3]thiadiazolo[5,4-b]pyridin-6-ylmethyl)amino]-1-piperidiny]methyl]-6-methoxy-, (α R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:610449 CAPLUS Full-text

DN 139:164798

TI Preparation of aminopiperidine derivatives for treatment of bacterial infections

IN Miller, William Henry; Pearson, Neil David; Pendrak, Israil; Seefeld, Mark

Andrew

PA Glaxo Group Limited, UK; Daines, Robert A

SO PCT Int. Appl., 96 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2003064421	A1	20030807	WO 2003-EP823	20030127	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	EP 1470125	A1	20041027	EP 2003-734701	20030127	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
	US 2005159411	A1	20050721	US 2003-502233	20030127	
	JP 2005525324	T	20050825	JP 2003-564044	20030127	
PRAI	GB 2002-2026	A	20020129			
	GB 2002-29824	A	20021220			
	WO 2003-EP823	W	20030127			
OS	MARPAT 139:164798					
GI						



AB Title compds. I [one of Z1-5 = N, one = CR1a and the remainder = CH or one of Z1-5 = CR1a and the remainder = CH; R1-1a = H, OH, alkoxy, amino, etc.; R2 = H, alkyl, alkenyl; R3 = CF3, 2-oxo, etc.; R4 = UR5; U = CO, SO2, CH2; R5 = bicyclic, heterocyclic ring system A; n = 0-1; AB = amido, alkylacyl, aminosulfonyl, etc.] are prepared For instance, bromomethyl (6-methoxy[1,5]naphthyridin-4-yl)ketone (preparation given) is reduced (PhMe, (+)-DIPCl) to give the (R)-alc., converted to the oxirane (MeOH, K2CO3) and

used to alkylate [(2S,4S)-2-(trifluoromethyl)piperidin-4-yl]carbamic acid tert-Bu ester (preparation given) and deprotected to give (1R)-2-[(2S,4S)-4-amino-2-(trifluoromethyl)piperidin-1-yl]-1-(6-methoxy[1,5]naphthyridin-4-yl)ethanol. This amine is alkylated with 3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carboxaldehyde (preparation given) (EtOH, NaBH₄) to give II. Selected examples have MICs ≤ 2 µg/mL vs., e.g., *S. epidermidis* CL7, *S. aureus* WCUH29, etc.

IT 577691-48-6P, 6-[[[(2S,4S)-1-[(R)-2-Hydroxy-2-(6-methoxy[1,5]naphthyridin-4-yl)ethyl]-2-(trifluoromethyl)piperidin-4-yl]amino]methyl]-4H-benzo[1,4]thiazin-3-one


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminopiperidine derivs. for treatment of bacterial infections)

RN 577691-48-6 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[[[(2S,4S)-1-[(2R)-2-hydroxy-2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-2-(trifluoromethyl)-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:555350 CAPLUS Full-text

DN 137:125092

TI Preparation of 4-piperidinylquinolines and nitrogenated analogs as antibacterial agents

IN Davies, David Thomas; Jones, Graham Elgin; Markwell, Roger Edward; Miller, William; Pearson, Neil David

PA Smithkline Beecham P.L.C., UK

SO PCT Int. Appl., 94 pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002056882	A1	20020725	WO 2002-EP587	20020122
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,				

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 EP 1359908 A1 20031112 EP 2002-702296 20020122
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004520360 T 20040708 JP 2002-557390 20020122
 US 2004138219 A1 20040715 US 2004-466394 20040126
 PRAI GB 2001-1577 A 20010122
 WO 2002-EP587 W 20020122
 OS MARPAT 137:125092
 GI



I



II

AB Title compds. I [wherein one of Z1-Z5 = N, one = CR1a, and the remainder = CH; or one of Z1-Z5 = CR1a and the remainder = CH; R1 and R1a = independently H, OH, or (un)substituted alkoxy; R2 = H or (un)substituted alkyl or alkenyl; R3 = H, carboxy, alkoxycarbonyl, alkenyloxycarbonyl, or (un)substituted aminocarbonyl, alkyl, or ethenyl; R4 = UR5; U = CO, SO2, or CH2; R5 = (un)substituted bicyclic carbocyclic or heterocyclic ring; n = 0 and AB = (un)substituted NHCO, COCH2, CH2CO, NHSO2, CH2SO2, or CH2CH2; or n = 0 and AB = NHCO, COCH2, CH2CO, NHSO2, CONH, CH2CH2, OCH2, or NHCH2; with provisos; and pharmaceutically derivs. thereof] were prepared for the treatment of gram pos. and gram neg. bacterial infections in mammals, particularly in man. For example, quinone was treated with t-BuOK in t-BuOH and H2O to give 6-methoxyquinoline-4-carboxylic acid (46%), which was converted to (R)-2-(6-methoxyquinoline-4-yl)oxirane over several steps. Reaction with LiClO4 in anhydrous DMF, 4-tert-butoxycarbonylaminopiperidine•HCl, and K2CO3 with heating to 90° for 26 h afforded 4-tert-butoxycarbonylamino-1-[2-(R)-hydroxy-2-(6-methoxyquinoline-4-yl)ethyl]piperidine. Deprotection, condensation with 2,3-dihydrobenzo[1,4]dioxin-6-carboxaldehyde, and conversion to the salt gave II•2HO2CCO2H. The latter demonstrated antibacterial activity with MIC ≤ 0.125 μM against one or more of the gram pos. and gram neg. bacteria tested.

IT 443955-94-0P, 6-[[[(3S,4S)-3-Hydroxy-1-[(R)-2-hydroxy-2-(6-methoxyquinolin-4-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-benzo[1,4]thiazin-3-one
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(antibacterial agent; preparation of piperidinylquinolines and nitrogenated analogs as antibacterial agents)

RN 443955-94-0 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[[[(3S,4S)-3-hydroxy-1-[(2R)-2-hydroxy-2-(6-methoxy-4-quinolinyl)ethyl]-4-piperidinyl]amino]methyl]- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:90042 CAPLUS Full-text
DN 136:151082
TI Preparation of aminopiperidine quinolines and their azaisosteric analogs
having antibacterial activity
IN Davies, David Thomas; Jones, Graham Elgin; Lightfoot, Andrew P.; Markwell,
Roger Edward; Pearson, Neil David
PA Smithkline Beecham P.L.C., UK
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002008224	A1	20020131	WO 2001-EP8604	20010725
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2417192	A1	20020131	CA 2001-2417192	20010725
EP 1305308	A1	20030502	EP 2001-969509	20010725
EP 1305308	B1	20061220		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012750	A	20030909	BR 2001-12750	20010725
JP 2004504397	T	20040212	JP 2002-514130	20010725
NZ 523749	A	20050324	NZ 2001-523749	20010725
HU 200300721	A2	20050829	HU 2003-721	20010725
AT 348826	T	20070115	AT 2001-969509	20010725
ZA 2003000589	A	20040422	ZA 2003-589	20030122
NO 2003000345	A	20030310	NO 2003-345	20030123
IN 2003MN00103	A	20050204	IN 2003-MN103	20030123

10/502,233

US 2004038998	A1	20040226	US 2003-333829	20030828
US 6962917	B2	20051108		
US 2006014749	A1	20060119	US 2005-219148	20050902
PRAI GB 2000-18351	A	20000726		
GB 2001-1629	A	20010122		
WO 2001-EP8604	W	20010725		
US 2003-333829	A3	20030828		
OS MARPAT 136:151082				
GI				



I



II

AB Aminopiperidine quinoline compds. I (Z1-Z5 = one is N, one (or two independently are) CR1a and the remainder are CH; R1 and R1a = independently are H, OH, NH2, CONH2, halogen, (un)substituted S and SO2, (un)substituted alkyl and alkoxy, etc.; R2 = H, (un)substituted alkyl or alkenyl; R3 = H, CO2H, (un)substituted amino, etc.; R4 = CO, SO2, CH2 attached to an optionally substituted bicyclic, carbocyclic or heterocyclic ring system; n = 0-1; AB = substituted N or C), their salts and pharmaceutically acceptable derivs. were prepared and found to be useful in treating bacterial infections in mammals, especially humans. Thus II was prepared from 4-amino-1-[2-(R)-hydroxy-2-(6-methoxyquinolin-4-yl)]ethylpiperidine and 5-bromo-1H-indole-2-carboxaldehyde and was determined to have an MIC less than or equal to 32µg/mL against one or more of gram pos. and neg. bacteria such as S. aureus Oxford and WCUH29 and S. pneumoniae 1629, N1387 and ERY 2.

IT 394222-56-1P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of aminopiperidine quinolines and their azaisosteric analogs having antibacterial activity)

RN 394222-56-1 CAPLUS

CN 4-Quinolinemethanol, α-[[4-[(1H-indol-2-ylmethyl)amino]-1-piperidinyl]methyl]-6-methoxy-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l4 and pd<jan 2002

22562206 PD<JAN 2002

(PD<20020100)

L5 0 L4 AND PD<JAN 2002

=> dis his

(FILE 'HOME' ENTERED AT 10:44:51 ON 27 FEB 2007)

FILE 'REGISTRY' ENTERED AT 10:45:02 ON 27 FEB 2007

L1 STRUCTURE UPLOADED

L2 6 S L1 SAM

L3 615 S L1 FULL

FILE 'CAPLUS' ENTERED AT 10:45:38 ON 27 FEB 2007

L4 6 S L3

L5 0 S L4 AND PD<JAN 2002

=> log y

STN INTERNATIONAL LOGOFF AT 10:46:43 ON 27 FEB 2007